1. Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients.
- Author
-
Bracke A, De Hert E, De Bruyn M, Claesen K, Vliegen G, Vujkovic A, van Petersen L, De Winter FHR, Hotterbeekx A, Brosius I, Theunissen C, Van Ierssel S, van Frankenhuijsen M, Vlieghe E, Vercauteren K, Van der Veken P, Hendriks D, Kumar-Singh S, and De Meester I
- Subjects
- Carboxypeptidases, Dipeptidyl Peptidase 4, Endopeptidases, Gelatinases, Humans, Membrane Proteins, Peptide Hydrolases, Proline, Serine Endopeptidases, COVID-19, Shock, Septic
- Abstract
Background: COVID-19 patients experience several features of dysregulated immune system observed in sepsis. We previously showed a dysregulation of several proline-selective peptidases such as dipeptidyl peptidase 4 (DPP4), fibroblast activation protein alpha (FAP), prolyl oligopeptidase (PREP) and prolylcarboxypeptidase (PRCP) in sepsis. In this study, we investigated whether these peptidases are similarly dysregulated in hospitalized COVID-19 patients., Methods: Fifty-six hospitalized COVID-19 patients and 32 healthy controls were included. Enzymatic activities of DPP4, FAP, PREP and PRCP were measured in samples collected shortly after hospital admission and in longitudinal follow-up samples., Results: Compared to healthy controls, both DPP4 and FAP activities were significantly lower in COVID-19 patients at hospital admission and FAP activity further decreased significantly in the first week of hospitalization. While PRCP activity remained unchanged, PREP activity was significantly increased in COVID-19 patients at hospitalization and further increased during hospital stay and stayed elevated until the day of discharge., Conclusion: The changes in activities of proline-selective peptidases in plasma are very similar in COVID-19 and septic shock patients. The pronounced decrease in FAP activity deserves further investigation, both from a pathophysiological viewpoint and as its utility as a part of a biomarker panel., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF